T-Cell Therapy Market
Number of pages: 100 | Report Format: PDF | Published date: February 15, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 5.3 billion |
|
Revenue Forecast in 2030 |
US$ 25 billion |
|
CAGR |
19.1% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Type, Modality, Indication, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global T-cell therapy market was valued at US$ 5.3 billion in 2021 and is expected to register a revenue CAGR of 19.1% to reach US$ 25 billion by 2030.
T-cell Therapy Market Fundamentals
T-cell therapy, also known as T-cell immunotherapy, is a type of cancer treatment that harnesses the power of the body’s own immune system to fight cancer cells. T-cells are a type of white blood cell that play a crucial role in the immune system’s ability to recognize and destroy cells that are foreign or abnormal, such as cancer cells. T-cell therapy works by collecting T-cells from a patient’s blood, modifying them in a laboratory to recognize and attack specific cancer cells, and then infusing the modified T-cells back into the patient’s bloodstream. The modified T-cells then work to destroy the cancer cells and continue to multiply and persist in the body, providing ongoing protection against cancer recurrence.
The T-cell therapy market is a rapidly growing field within the larger immunotherapy market, driven by advances in cancer research and the increasing recognition of the potential benefits of T-cell-based treatments. T-cell therapy has shown promising results in the treatment of various types of cancer, including lymphoma and leukemia, and is being explored for the treatment of other diseases, including solid tumors and autoimmune disorders. The market for T-cell therapy is expected to continue growing in the coming years, driven by factors such as technological advances and growing investment in research and development activities.
Despite the positive outlook for the T-cell therapy market, the high cost of these treatments and the potential for side effects and other safety concerns remain challenges. Efforts to reduce costs and improve access to T-cell therapy for more patients are expected to be an important factor in the continued growth of the market.
[576576]
T-cell Therapy Market Dynamics
The increasing incidence of cancer worldwide, particularly in developed countries, is driving demand for new and effective cancer treatments, including T-cell therapy. According to GLOBOCAN 2020 report, around 19 million new cases of cancer were detected in 2020. The T-cell therapy market has seen a significant increase in investment, as well as research and development efforts, as companies and organizations aim at bringing new and more effective treatments, which is boosting revenue growth in the T-cell therapy market. T-cell therapy is being explored for the treatment of a growing number of cancer types and other diseases, including solid tumors and autoimmune disorders, leading to a wider range of potential patients and a growing T-cell therapy market. As T-cell therapy continues to gain recognition as a promising treatment option, regulatory agencies, such as the U.S. FDA, are increasing their focus on the development and approval of T-cell therapies. Moreover, the T-cell therapy market is driven by technological advancements, including improvements in cell manufacturing processes, the development of new delivery methods, and the discovery of new target antigens. Additionally, the growing awareness about T-cell therapy as a promising treatment option for cancer is driving increased interest and investment in the field, leading to the development of new and improved treatments.
However, the high cost related to T-cell therapy is restricting the market revenue growth. T-cell therapy is still in its early stages of development and, as a result, is only available in a limited number of centers worldwide. Moreover, there are some side effects associated with the therapy. These factors are also hampering the revenue growth of the global T-cell therapy market.
T-cell Therapy Market Ecosystem
The global T-cell therapy market has been analyzed from four perspectives: type, modality, indication, and region.
T-cell Therapy Market by Type
[8756757]
Based on type, the market for T-cell therapy is segmented into CAR T-cell therapy, T-cell receptor (TCR)-based, and tumor-infiltrating lymphocytes (TIL)-based.
The CAR T-cell therapy segment dominated the global T-cell therapy market in 2021. CAR T-cell therapy has demonstrated remarkable efficacy in the treatment of various types of cancer, including lymphoma and leukemia, which has helped to establish its position as a leading T-cell therapy. CAR T-cell therapy has received regulatory approvals in several countries, including the U.S., Europe, and China, which has helped to increase patient access to these treatments and has contributed to its dominance in the market. The growing demand for immune-based therapies for cancer treatment has driven increased interest and investment in CAR T-cell therapy, helping to establish its dominant position in the T-cell therapy market. The growing body of clinical evidence supporting the safety and efficacy of CAR T-cell therapy has helped to establish its dominant position in the market and has driven increased patient demand for these treatments.
T-cell Therapy Market by Modality
Based on modality, the global T-cell therapy market is segmented into research and commercialized.
The research segment accounted for the largest revenue share of the T-cell therapy market in 2021. The increasing demand for immune-based therapies for cancer treatment has driven significant research efforts in T-cell therapy, particularly in the development of new and improved treatments. The continuous advancements in T-cell therapy technology, such as the development of CAR T-cell therapy, have led to increased interest and investment in T-cell therapy research, helping to establish the research segment as a dominant player in the market. The high unmet need for effective cancer treatments has steered increased investment and research efforts in T-cell therapy, as it has the potential to offer a new and effective approach to cancer treatment.
T-cell Therapy Market by Indication
Based on indication, the global T-cell therapy market is segmented into hematologic malignancies, solid tumors, and others.
The hematologic malignancies segment accounted for a significant revenue share of the T-cell therapy market in 2021. The hematologic malignancies segment is further sub-segmented into lymphoma, leukemia, and myeloma. Hematologic malignancies, such as leukemia and lymphoma, are some of the most common types of cancer, which has fueled the demand for effective treatments and has helped to establish the hematologic malignancies segment’s dominance in the T-cell therapy market. According to GLOBOCAN 2020 report, about 474,519, or around 2.6% of cancer cases, are of leukemia. There is a growing body of clinical evidence supporting the safety and efficacy of T-cell therapy in the treatment of hematologic malignancies, which has helped to drive increased patient demand for these treatments and has contributed to the dominance of the hematologic malignancies segment in the T-cell therapy market. T-cell therapy, particularly CAR T-cell therapy, has demonstrated remarkable efficacy in the treatment of hematologic malignancies, which boosts segmental growth.
T-cell Therapy Market by Region
Based on region, the global T-cell therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global T-cell therapy market in 2021, followed by Europe and Asia Pacific. The market in North America has a high prevalence of cancer, which has driven demand for effective cancer treatments and has helped to support the growth of the T-cell therapy market. According to the American Cancer Society in the U.S., there is an estimated 1.9 million new cancer cases diagnosed in 2022. North America has a strong healthcare infrastructure, which helps to provide the necessary infrastructure and resources to support research and development efforts, as well as patient access to these treatments. There has been a growing awareness of T-cell therapy, including CAR T-cell therapy, among patients and healthcare providers in North America, which has fueled the demand for these treatments and has driven revenue growth in the T-cell therapy market.
T-cell Therapy Market Competitive Landscape
The prominent players operating in the T-cell therapy market are:
T-cell Therapy Market Strategic Developments
T-cell therapy, also known as T-cell immunotherapy, is a type of cancer treatment that harnesses the power of the body’s own immune system to fight cancer cells. T-cells are a type of white blood cell that play a crucial role in the immune system’s ability to recognize and destroy cells that are foreign or abnormal, such as cancer cells.
Novartis AG, Merck KGaA, Gilead Sciences Inc., Bristol-Myers Squibb Company, and Pfizer Inc. are among the top market players.
The CAR T-cell therapy segment dominates the global T-cell therapy market.
The CAR T-cell therapy market was valued at US$ 5.3 billion in 2021.
The T-cell therapy market is estimated to register growth at a revenue CAGR of 19.1% during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain